Cytokine Adaptor Proteins for Tissue-Specific Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cytokine therapies face challenges in achieving context-dependent cytokine agonism and antagonism due to pleiotropy and broad expression of cytokine receptors, leading to ineffective treatment of diseases like cancer and autoimmune disorders, where immune cells in the tumor microenvironment are suppressed, and pro-inflammatory environments contribute to autoimmune conditions.
Innovation Solution
Development of cytokine adaptors, which are bi-specific binding proteins that alter receptor/ligand interactions by binding to tumor-associated or pro-inflammatory cytokines and converting suppressive signals into activating stimuli, using specific binding domains to target and activate immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytokine receptor agonists are used to treat diseases, then immune activation is achieved, but off-target effects occur due to broad expression of cytokine receptors in multiple tissues
Solution Approach 1:
The patent applies local quality by creating context-dependent cytokine agonism where the same cytokine agonist produces different effects in different tissues based on the local cytokine receptor environment. The agonist is activated only in tissues where the specific cytokine-receptor pairing occurs, achieving tissue-specific effects without requiring tissue-selective drug delivery.
Solution Approach 2:
The patent introduces dynamics by making cytokine receptor activation context-dependent rather than static. The same agonist can dynamically switch between activating different signaling pathways depending on the local microenvironment, allowing a single agent to adapt its effect based on tissue-specific receptor expression and cytokine availability.
2Adaptability or versatility
If broad-spectrum cytokine therapies are used to address multiple functions, then therapeutic coverage is improved, but loss of specificity leads to inability to treat context-dependent diseases
Solution Approach 1:
The patent applies universality by designing cytokine agonists that can function across multiple tissues and disease contexts, yet maintain context-specific activity through dependence on local cytokine-receptor pairing. The same agonist structure can be used in cancer, autoimmune disease, and infection by leveraging naturally occurring cytokine-receptor interactions in each context.
Solution Approach 2:
The patent utilizes parameter changes by altering the activation threshold and signaling outcome based on local cytokine concentration and receptor expression levels. The agonist's effectiveness is modulated by the local biochemical environment, allowing it to be activated only when the specific cytokine-receptor pairing is present, thus adapting to different disease contexts.
3Object-affected harmful factors
If cytokine antagonists are used to block pro-inflammatory cytokines, then inflammation is reduced, but immune suppression increases leading to poor anti-tumor response
Solution Approach 1:
The patent applies inversion by reversing the conventional approach from pure antagonism to context-dependent agonism. Instead of broadly blocking all cytokine receptors, the invention uses agonists that selectively activate protective immune functions in specific contexts where the cytokine-receptor pairing is beneficial, such as anti-tumor immunity, while avoiding activation in contexts where inflammation is harmful.
Solution Approach 2:
The patent introduces intermediary cytokine agonists that mediate between the tumor microenvironment and the immune system. These agonists respond to local cytokine signals and translate them into appropriate immune responses, acting as intermediaries that convert suppressive cytokine signals into activating immune signals only when the context is appropriate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cytokine adaptors effectively convert suppressive signals to activating stimuli, enhancing immune responsiveness against tumors or reducing pro-inflammatory cytokine levels in autoimmune diseases, thereby preventing or treating associated conditions.
Implementation Method 1
Cytokine adaptors are bi-specific binding proteins that alter the specificity, e.g. the signaling pathway that is activated, of a receptor/ligand interaction. The adaptors can act by binding to a tumor-associated protein, e.g. an immunosuppressive cytokine, and a pro-inflammatory receptor, to convert a suppressive signal into an activating stimulus.
Data Source
AI summary
Cytokine adaptors, compositions comprising cytokine adaptors, and methods of use thereof, are provided. Cytokine adaptors are bi-specific binding proteins that alter the specificity of a receptor/ligand interaction. The adaptors generally act by simultaneously binding to a target protein and a receptor to drive a context-dependent response.